Toxins 2010, 2(12), 2872-2889; doi:10.3390/toxins2122872
Article

Strategy for Treating Motor Neuron Diseases Using a Fusion Protein of Botulinum Toxin Binding Domain and Streptavidin for Viral Vector Access: Work in Progress

1,* email, 1email, 1email and 2email
Received: 11 October 2010; in revised form: 16 December 2010 / Accepted: 17 December 2010 / Published: 20 December 2010
(This article belongs to the Special Issue Toxins as Therapeutics)
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract: Although advances in understanding of the pathogenesis of amyotrophic lateral sclerosis (ALS) and spinal muscular atrophy (SMA) have suggested attractive treatment strategies, delivery of agents to motor neurons embedded within the spinal cord is problematic. We have designed a strategy based on the specificity of botulinum toxin, to direct entry of viral vectors carrying candidate therapeutic genes into motor neurons. We have engineered and expressed fusion proteins consisting of the binding domain of botulinum toxin type A fused to streptavidin (SAv). This fusion protein will direct biotinylated viral vectors carrying therapeutic genes into motor nerve terminals where they can enter the acidified endosomal compartments, be released and undergo retrograde transport, to deliver the genes to motor neurons. Both ends of the fusion proteins are shown to be functionally intact. The binding domain end binds to mammalian nerve terminals at neuromuscular junctions, ganglioside GT1b (a target of botulinum toxin), and a variety of neuronal cells including primary chick embryo motor neurons, N2A neuroblastoma cells, NG108-15 cells, but not to NG CR72 cells, which lack complex gangliosides. The streptavidin end binds to biotin, and to a biotinylated Alexa 488 fluorescent tag. Further studies are in progress to evaluate the delivery of genes to motor neurons in vivo, by the use of biotinylated viral vectors.
Keywords: botulinum toxin; binding domain; motor neuron diseases; ALS; SMA; motor neurons; therapeutic targeting; gene transfer; viral vectors
PDF Full-text Download PDF Full-Text [644 KB, uploaded 20 December 2010 16:11 CET]

Export to BibTeX |
EndNote


MDPI and ACS Style

Drachman, D.B.; Adams, R.N.; Balasubramanian, U.; Lu, Y. Strategy for Treating Motor Neuron Diseases Using a Fusion Protein of Botulinum Toxin Binding Domain and Streptavidin for Viral Vector Access: Work in Progress. Toxins 2010, 2, 2872-2889.

AMA Style

Drachman DB, Adams RN, Balasubramanian U, Lu Y. Strategy for Treating Motor Neuron Diseases Using a Fusion Protein of Botulinum Toxin Binding Domain and Streptavidin for Viral Vector Access: Work in Progress. Toxins. 2010; 2(12):2872-2889.

Chicago/Turabian Style

Drachman, Daniel B.; Adams, Robert N.; Balasubramanian, Uma; Lu, Yang. 2010. "Strategy for Treating Motor Neuron Diseases Using a Fusion Protein of Botulinum Toxin Binding Domain and Streptavidin for Viral Vector Access: Work in Progress." Toxins 2, no. 12: 2872-2889.

Toxins EISSN 2072-6651 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert